BLRX Beats Earnings, Misses Revenue as Stock Dives

BioLineRx (BLRX) reported fiscal 2025 Q4 earnings on March 23, 2026, with GAAP EPS of $0.00, beating estimates by $0.68, though revenue of $1.94 million missed expectations by $0.3 million. The company maintained its cash runway guidance into mid-2027 and outlined strategic advancements in its pipeline.

Revenue

The total revenue of BioLineRx decreased by 98.3% to $194,000 in 2025 Q4, down from $11.75 million in 2024 Q4.

Earnings/Net Income

BioLineRx narrowed its net loss to $-2.24 million in 2025 Q4, a 29.8% improvement from the $-3.19 million loss in 2024 Q4. The company achieved a record high for Q4 net income in two years, reflecting operational efficiency gains. Despite the EPS remaining unchanged at $0.00 per share, the reduced net loss signals progress toward financial stability.

Price Action

The stock price of BioLineRx has tumbled 10.42% during the latest trading day, 11.79% during the most recent full trading week, and 17.73% month-to-date.

Post-Earnings Price Action Review

The strategy of buying BioLineRx (BLRX) shares after a revenue drop quarter-over-quarter on the financial report release date and holding for 30 days resulted in a significant loss. Over the past three years, this strategy yielded a return of -96.90%, underperforming the benchmark by 141.23%. The strategy's Sharpe ratio was -0.63, indicating substantial risk, while the maximum drawdown was 97.91%, highlighting the strategy's vulnerability during market downturns.

CEO Commentary

Philip Serlin, CEO, emphasized GLIX1 as the company’s “new vision,” citing its first-in-class potential for glioblastoma and other cancers. He highlighted the molecule’s blood-brain barrier penetration, favorable safety profile, and plans for a Phase I/IIa trial by March 2026. With $21 million in cash, the company aims to fund operations through mid-2027 while advancing motixafortide trials in pancreatic cancer and sickle cell disease.

Guidance

The CEO confirmed the company’s cash runway extends into the first half of 2027, with Phase I data for GLIX1 expected in H1 2027.

Additional News

BioLineRx secured a Notice of Allowance for GLIX1 patent protection through 2040, extending exclusivity and market potential. The company initiated a Phase I/IIa glioblastoma trial for GLIX1 in March 2026, with Phase I data anticipated in 2027. Additionally, BioLineRx resolved a legal dispute with Biokine, enabling focused R&D efforts. Interim analysis for motixafortide in pancreatic cancer is expected in 2026, positioning the company for potential value inflection points.